Sign in →

Test Code CA19-9 Carbohydrate Antigen 19-9 (CA 19-9), Serum

Additional Codes

Mayo Test ID
CA19

Reporting Name

Carbohydrate Ag 19-9, S

Useful For

As a potential adjunct for diagnosis and monitoring of pancreatic cancer

 

Potentially differentiating patients with cholangiocarcinoma and primary sclerosing cholangitis (PSC) from those with PSC alone

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Serum


Specimen Required


Patient Preparation: For 12 hours before specimen collection, patient should not take multivitamins or dietary supplements (eg, hair, skin, and nail supplements) containing biotin (vitamin B7).

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.6 mL

Collection Instructions:

1. Within 2 hours of collection, serum gel tubes should be centrifuged.

2. Within 2 hours of collection, red-top tubes should be centrifuged, and the serum aliquoted into a plastic vial.


Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 7 days
  Frozen  90 days
  Ambient  8 hours

Reference Values

<35 U/mL

Day(s) Performed

Monday through Saturday

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

86301

LOINC Code Information

Test ID Test Order Name Order LOINC Value
CA19 Carbohydrate Ag 19-9, S 83084-4

 

Result ID Test Result Name Result LOINC Value
CA19 Carbohydrate Ag 19-9, S 83084-4

Clinical Information

Carbohydrate antigen 19-9 (CA 19-9) is a modified Lewis(a) blood group antigen. CA 19-9 may be elevated in patients with gastrointestinal malignancies such as cholangiocarcinoma, pancreatic cancer, or colon cancer.

 

Benign conditions, such as cirrhosis, cholestasis, and pancreatitis, also result in elevated serum CA 19-9 concentrations, but in these cases, values are usually below 1000 U/mL.

 

Individuals that are Lewis antigen negative (5%-7% of the population) do not express CA 19-9 due to the lack of the enzyme fucosyltransferase needed for CA 19-9 production. In these individuals, a low or undetectable serum CA 19-9 concentration is not informative regarding cancer recurrence.

Interpretation

Serial monitoring of carbohydrate antigen 19-9 (CA 19-9) should begin prior to therapy to verify post therapy decreases in CA 19-9 and to establish a baseline for evaluating possible recurrence. Single values of CA 19-9 are less informative.

 

Elevated values may be caused by a variety of malignant and nonmalignant conditions including cholangiocarcinoma, pancreatic cancer, and colon cancer.

Cautions

Carbohydrate antigen 19-9 (CA 19-9) is neither specific nor sensitive enough to be used as a cancer screen.

 

Some individuals do not express CA 19-9. Consequently, low values in these individuals are not informative regarding cancer recurrence.

 

Serum CA 19-9 levels should not be interpreted as absolute evidence of the presence or absence of malignant disease. Instead, serum CA 19-9 results should be used in conjunction with information from the clinical evaluation of the patient and other diagnostic procedures.

 

Some patients who have been exposed to animal antigens, either in the environment or as part of treatment or imaging procedures, may have circulating anti-animal antibodies present. These antibodies may interfere with the assay reagents and produce unreliable results.

Report Available

1 to 3 days

Reject Due To

Gross hemolysis Reject
Gross lipemia OK
Gross Icterus OK

Forms

If not ordering electronically, complete, print, and send Oncology Test Request (T729)

Method Name

Immunoenzymatic Assay